Pharmanovia acquires CNS portfolio from Sanofi

UK-based lifecycle management and pharma manufacturing company Pharmanovia today announced the expansion of its neurology portfolio with the acquisition of 11 central nervous system (CNS) brands from French pharma major Sanofi (Euronext: SAN).

Pharmanovia says this marks a significant milestone for the company, as its brand portfolio now covers four critical areas of unmet needs related to CNS disorders: psycholeptic, anxiolytic, anti-epileptic, and anti-psychotic medications. No financial terms of the transaction were revealed.

One of the drugs is Frisium (clobazam), which is from a class of medicines called benzodiazepines and can be used to treat anxiety, with or without insomnia or certain psychiatric conditions, in certain patients. Clobazam is also marketed under the trade names Sentil, Urbanyl, Urbanil, Urbanol, Urbadan, Noiafren and Castilium. Frisium may also be used as adjunctive therapy in epilepsy.